The U.S. has its first publicly available adjuvanted seasonal flu vaccine in Fluad, formerly a Novartis shot that is now owned by CSL's Seqirus unit.
The U.S. may be getting its first adjuvanted flu vaccine. On Tuesday, an FDA panel recommended accelerated approval of Novartis' Fluad--now owned by CSL's flu vaccine subsidiary--in individuals 65 and older.
After last week partially banning Novartis' Fluad, Italian officials now say tests on the flu vaccine show the product is safe.
Italy's drug regulator has a growing investigation on its hands, and Novartis is in the middle of it. The number of people who have died in the country after receiving one of the Swiss pharma giant's flu vaccines has risen by 10 just days after Italy issued a partial ban on the product.
Switzerland's suspension of Novartis flu vaccines Agrippal and Fluad was short-lived--and Canada's was even shorter. Both countries have lifted their bans on the immunizations, saying their own lab analyses, plus information from Novartis, confirmed their safety.
Health Canada said it would suspend the shots, following similar moves by European regulators, because of clumped-together virus particles found in the Italian-made vials.